Fab’entech

Fab’entech is a French biotech created in 2009 and specialised in the development and production of polyclonal antibodies intended for the treatment of emerging infectious diseases and biodefense solutions. Lifestyles, the globalisation of exchanges, the relationship of humans to nature raise fears of multiplying pandemics in the coming years. Fab’entech offers a modular technological platform which allows the rapid development of effective treatments to deal with the emergence of new infectious diseases or biological threats. The production of polyclonal antibodies by Fab’entech is based on a safe and proven technology, initially developed by Sanofi Pasteur and enhanced for more than 10 years by the Research & Development teams at Fab’entech. Fab’entech thus combines the know-how and experience of a large pharmaceutical company with the agility of a biotech.